Delpharm acquires injectable drug development center in the Netherlands from Dr Reddy's

By Jane Byrne

- Last updated on GMT

© GettyImages/MarsBars
© GettyImages/MarsBars

Related tags Dr Reddy's Delpharm Injectables

France headquartered CDMO, Delpharm, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Centre from Dr Reddy's in the Netherlands.

The financial outlay was not disclosed. 

The Dutch facility, which was established in 1995, spans 3,500 square meters, and it is equipped with technologies to develop injectable formulations for small and large molecules and to manufacture small batches for clinical trials, reported the contract development and manufacturing organization (CDMO). 

Together with the new unit, the French firm said it will benefit from the transfer of the 40 “highly qualified​” employees from the Dr Reddy's center to its organization. Globally, the CDMO employs over 6,000 people.

With the acquisition of the Leiden site, Delpharm said it is now positioned as a complete player in injectable, from formulation, analytical development, Phase 1 clinical batches manufacturing, through to regulatory affairs and production. 

In 2021, Delpharm was selected by Pfizer/BioNTech to support the manufacture​ of its COVID-19 vaccine at its plant in Saint-Rémy-sur-Avre, with tens of millions of doses eventually coming from that site. Delpharm recruited around 60 more people at that facility to support the production.

Along with this new sterile development center, Delpharm has 11 manufacturing sites in France, two in Italy, three in Canada, one in the Netherlands, and another unit in Poland, providing the majority of available dosage forms on the market: tablets, injectable vials, ampoules, prefilled syringes, freeze dry, suspensions, solutions, ointments and soft gels. In addition, the developer outlined how it has the required expertise to develop and manufacture complex formulations such as liposome, suspension, microsphere, sustained release, and emulsion.

“We are also making significant investments in our injectable manufacturing facilities throughout the world to offer a one stop shop service to our clients, speeding up the access of new medicines for the patients,"​ added Jean-Bernard Dumas, chief scientific officer, Delpharm. 

Such facility modifications include a new prefilled syringe line for its Tours plant. "We also are building a new unit in order to install a sterile vial line at our Saint-Rémy plant,"​ a spokesperson for Delpharm told us.

The company reported that its overall activities registered €1bn (US$1.06bn) in revenue in 2022.

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers